A study by Chen (65) indicated that enzalutamide resistance-associated lncRNA NONHSAT-210528 can function as a competitive endogenous RNA (ceRNA) that promotes prostate cancer cell invasion and drug resistance through the miR-21-5p/YOD1 signaling pathway. The gene discussed is YOD1; the disease is prostate carcinoma.